Bleomycin
- Generic Name
- Bleomycin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C55H84N17O21S3
- CAS Number
- 11056-06-7
- Unique Ingredient Identifier
- 40S1VHN69B
- Background
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
- Indication
For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
- Associated Conditions
- Hodgkin's Lymphoma, Malignant Pleural Effusion, Non-Hodgkin's Lymphomas, Squamous Cell Carcinoma (SCC), Teratocarcinoma, Testicular Choriocarcinoma, Testicular Embryonal Carcinoma
- Associated Therapies
- Palliative Treatment
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT01873326
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Dose Escalating Study for Amphinex-based PCI of Bleomycin.
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- PCI Biotech AS
- Target Recruit Count
- 3
- Registration Number
- NCT01872923
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-23
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1334
- Registration Number
- NCT01712490
GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 671
- Registration Number
- NCT01659099
- Locations
- 🇧🇪
Clinique universitaire Saint LUC, Bruxelles, Belgium
🇧🇪CHU Ambroise Paré, Mons, Belgium
🇧🇪Clinique Sainte Elisabeth, Namur, Belgium
Prospective Study on HIV-related Hodgkin Lymphoma
- Conditions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2011-11-09
- Lead Sponsor
- Harlachinger Krebshilfe e.V.
- Target Recruit Count
- 130
- Registration Number
- NCT01468740
- Locations
- 🇩🇪
Infektionsmedizinisches Zentrum Hamburg, Hamburg, Germany
🇩🇪Vivantes Auguste Victoria Klinikum, Berlin, Germany
🇩🇪Ärzteforum Seestrasse, Berlin, Germany
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT01404936
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 6
- Registration Number
- NCT01390584
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center, Reading, Pennsylvania, United States
Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations
- Conditions
- Interventions
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT01347294
- Locations
- 🇳🇴
Oslo Universitetssykehus Rikshospitalet, Oslo, Norway
Electrochemotherapy as a Palliative Treatment for Brain Metastases
- Conditions
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2013-07-31
- Lead Sponsor
- Copenhagen University Hospital at Herlev
- Target Recruit Count
- 1
- Registration Number
- NCT01322100
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰Herlev Hospital, Herlev, Denmark
Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Fondazione Michelangelo
- Target Recruit Count
- 331
- Registration Number
- NCT01251107
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale di Tumori di Milano, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.